sara m. tolaney, md, mph tells us about the outcomes of the monarch 2 study
Published 6 years ago • 22 plays • Length 1:10
Download video MP4
Download video MP3
Similar videos
-
1:55
sara m. tolaney, md, mph, shares outcomes from the impassion130 study in tnbc
-
1:54
sara m. tolaney, md, mph, shares outcomes from the monaleesa-7 trial
-
6:55
additional advances in triple-negative breast cancer research and trials: sara m. tolaney, md, mph
-
1:48
sara m. tolaney, md, mph discusses the tailorx study
-
1:38
sara m. tolaney, md, mph, discusses the fulvestrant ribociclib arm of the monaleesa-3 study
-
3:13
sara tolaney md, mph shares results from the phase 2 atempt trial at sabcs 2019
-
1:58
sara m. tolaney, md, mph on whether cdk4/6 inhibitors can be used interchangeably
-
1:49
sabcs22: sara tolaney, md, mph | dana-farber cancer institute
-
4:19
abemaciclib plus nsai for hr , her2- advanced breast cancer - monarch 3 interim data
-
9:31
new options for immunotherapy trials
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:45
asco23: sara tolaney, md, mph | dana-farber cancer institute
-
3:01
dr sara m. tolaney discusses the role of adjuvant therapy in her2-positive breast cancer
-
42:57
cellular immunotherapy for the treatment of multiple myeloma
-
1:41
dana-farber cancer institute | sara tolaney, md, mph, at sabcs 2020
-
6:30
sabcs 2023: a look into new research for inflammatory breast cancer
-
1:28
esmo22: breast cancer research by sara tolaney, md | dana-farber cancer institute
-
2:04
dr sara m. tolaney: standard of care, novel approaches for treatment of her2-positive breast cancer
-
0:59
treatment for early stage her2 breast cancer | dana-farber cancer institute
-
1:01:35
new frontiers in immuno-oncology for solid tumor treatment
-
1:06
asco22: breast cancer research by sara tolaney, md | dana-farber cancer institute
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
Clip.africa.com - Privacy-policy